Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T22:13:03.311Z.
Calculation as of: 2026-10-06T22:13:03.311Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 23d17170dcd90d56222e16e6e1c46ca5d6e49f0f5e08d353dc7d5f06f7b1586d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$9.63B
EV/EBIT Ratio
46.56x
TTM Avg
47.39x
3Y Avg
65.45x
5Y Avg
65.45x
Market Cap
$9.66B
EV/EBIT Ratio
17.21x
TTM Avg
16.56x
3Y Avg
16.72x
5Y Avg
15.63x
Market Cap
$9.87B
EV/EBIT Ratio
152.42x
TTM Avg
3780.28x
3Y Avg
2036.57x
5Y Avg
1126.33x
Market Cap
$9.93B
EV/EBIT Ratio
45.17x
TTM Avg
40.04x
3Y Avg
33.82x
5Y Avg
33.08x
Market Cap
$10.03B
EV/EBIT Ratio
25.71x
TTM Avg
30.22x
3Y Avg
30.29x
5Y Avg
26.97x
Market Cap
$9.21B
EV/EBIT Ratio
86.49x
TTM Avg
55.05x
3Y Avg
39.77x
5Y Avg
33.84x
Market Cap
$10.13B
EV/EBIT Ratio
16.58x
TTM Avg
19.50x
3Y Avg
23.74x
5Y Avg
27.91x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vaxcyte, Inc. (PCVX) | $9.63B | N/A | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.63B | 46.56x | 47.39x | 65.45x | 65.45x |
| Henry Schein, Inc. (HSIC)vs › | $9.66B | 17.21x | 16.56x | 16.72x | 15.63x |
| Repligen Corporation (RGEN)vs › | $9.87B | 152.42x | 3780.28x | 2036.57x | 1126.33x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 45.17x | 40.04x | 33.82x | 33.08x |
| Insulet Corp. (PODD)vs › | $9.33B | 18.89x | 34.29x | 59.67x | 167.52x |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 25.71x | 30.22x | 30.29x | 26.97x |
| Bruker Corporation (BRKR)vs › | $9.21B | 86.49x | 55.05x | 39.77x | 33.84x |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 16.58x | 19.50x | 23.74x | 27.91x |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
